Borrelia, Babesia and Bartonella are stealth pathogens, low-abundance, slow-replicating organisms that suppress immune response and evade detection. Although lab-developed testing has improved, most diagnostics still rely on indirect markers, missing the root of the problem.
Every assay we use is optimized in-house and rigorously validated by our team of scientists to ensure clinical relevance, so providers get actionable results even when other tests fall short.
Nanotrap® technology captures and concentrates Borrelia antigens directly from urine, dramatically increasing sensitivity, especially in early-stage Lyme and complex chronic cases. Unlike antibody tests, it detects the pathogen itself, not the body’s immune response.
Galaxy's Digital PCR breaks samples into thousands of partitions, detecting trace amounts of pathogen DNA that other technologies miss. Originally pioneered in oncology, now adapted for infectious disease.
The most comprehensive Bartonella IgG IFA panel available, targeting the four species most associated with human disease, built using clinical isolates, not commercial slides and reported as titers.
Get the direct evidence needed to guide next steps, not just past exposure.
Helps you catch infections others miss, before they become harder to treat.
Vetted by published data, not just internal claims.
You shouldn’t need a specialist to interpret your results, though we’re here if you need us.
